ES2191973T3 - Composiciones farmaceuticas para la administracion oral de yodo molecular. - Google Patents

Composiciones farmaceuticas para la administracion oral de yodo molecular.

Info

Publication number
ES2191973T3
ES2191973T3 ES98954002T ES98954002T ES2191973T3 ES 2191973 T3 ES2191973 T3 ES 2191973T3 ES 98954002 T ES98954002 T ES 98954002T ES 98954002 T ES98954002 T ES 98954002T ES 2191973 T3 ES2191973 T3 ES 2191973T3
Authority
ES
Spain
Prior art keywords
iodine
molecular iodine
pharmaceutical compositions
oral administration
stomach
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98954002T
Other languages
English (en)
Inventor
Yongjun Duan
John Hickey
Rick Panicucci
Jack Kessler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symbollon Corp
Original Assignee
Symbollon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symbollon Corp filed Critical Symbollon Corp
Application granted granted Critical
Publication of ES2191973T3 publication Critical patent/ES2191973T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de una composición que comprende una cantidad efectiva de un oxidante farmacéuticamente aceptable para una especie de yodo y un reductor de yodo farmacéuticamente aceptable, conteniendo al menos uno de estos compuestos una especie de yodo, para la fabricación de un medicamento para tratar un trastorno de deficiencia de yodo en el que tiene lugar una reacción de oxidación- reducción in vivo tras el contacto de la composición con los jugos gástricos presentes en el estómago de un mamífero para generar yodo molecular en el estómago del mamífero a una relación de yodo molecular a yodo total por encima de al menos 0, 8.
ES98954002T 1997-10-29 1998-10-27 Composiciones farmaceuticas para la administracion oral de yodo molecular. Expired - Lifetime ES2191973T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/960,149 US5885592A (en) 1997-10-29 1997-10-29 Methods and pharmaceutical compositions for oral delivery of molecular iodine

Publications (1)

Publication Number Publication Date
ES2191973T3 true ES2191973T3 (es) 2003-09-16

Family

ID=25502851

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98954002T Expired - Lifetime ES2191973T3 (es) 1997-10-29 1998-10-27 Composiciones farmaceuticas para la administracion oral de yodo molecular.

Country Status (17)

Country Link
US (1) US5885592A (es)
EP (1) EP1024815B1 (es)
JP (1) JP4187410B2 (es)
KR (1) KR100412219B1 (es)
CN (1) CN1150904C (es)
AT (1) ATE231725T1 (es)
AU (1) AU750627B2 (es)
BR (1) BR9812588A (es)
CA (1) CA2301503C (es)
DE (1) DE69811105T2 (es)
DK (1) DK1024815T3 (es)
ES (1) ES2191973T3 (es)
IL (1) IL134778A0 (es)
NO (1) NO20001673L (es)
PT (1) PT1024815E (es)
RU (1) RU2213564C2 (es)
WO (1) WO1999021567A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248335B1 (en) * 1997-10-29 2001-06-19 Symbollon Corporation Stabilized oral pharmaceutical composition containing iodide and iodate and method
EP1044689A4 (en) * 1998-01-06 2002-07-03 Fujisawa Pharmaceutical Co SOLID IODOPHORE BASED PREPARATIONS AND MANUFACTURING METHOD THEREOF
EP1087800B1 (en) * 1998-06-19 2003-08-06 Oxibio, Inc. Implantable medical device having anti-infective and contraceptive properties
US6154672A (en) * 1998-06-22 2000-11-28 Pacesetter, Inc. Method and apparatus for improving the probability of success of defibrillation shocks
GB2395901A (en) * 1999-02-26 2004-06-09 Symbollon Corp Stabilised tablets containing iodide and iodate
PT1195178E (pt) * 2000-10-06 2006-10-31 Dmg Italia Srl Preparacao imunotrofica para o tratamento da hipertrofia adenoamigdalar.
AU2004249301B2 (en) * 2003-06-20 2011-01-20 Hill's Pet Nutrition, Inc. Methods for hyperthyroidism in a cat and composition comprising limited iodine
US8501223B2 (en) * 2003-06-20 2013-08-06 Hill's Pet Nutrition, Inc. Methods for dietary management of cats to avoid hyperthyroidism
DK2666366T3 (en) * 2006-01-26 2015-04-13 Hills Pet Nutrition Inc METHODS AND COMPOSITIONS FOR TREATING FELIN HYPERTHYROIDISM
AU2007249806B2 (en) * 2006-05-12 2011-07-07 Hill's Pet Nutrition, Inc. Compositions and methods for preventing or treating chronic renal failure in felines with hyperthyroidism
US8303994B2 (en) * 2006-06-22 2012-11-06 Jack Howard Kessler Method for the eradication of pathogens including S. aureus and antibiotic resistant microbes from the upper respiratory tract of mammals and for inhibiting the activation of immune cells
ES2402077T3 (es) * 2006-07-03 2013-04-26 Hill's Pet Nutrition, Inc. Composiciones y métodos para la prevención o el tratamiento de enfermedades cardiovasculares en felinos con hipertiroidismo
US8021610B2 (en) * 2006-09-07 2011-09-20 Biolargo Life Technologies, Inc. Systems providing antimicrobial activity to an environment
US9414601B2 (en) * 2006-09-07 2016-08-16 Biolargo Life Technologies, Incorporated Material having antimicrobial activity when wet
US20080063560A1 (en) * 2006-09-07 2008-03-13 Biolargo Life Technologies, Incorporated Ground treatment for reducing microbial content
US8226964B2 (en) * 2006-09-07 2012-07-24 Biolargo Life Technologies, Inc. Systems and methods for cleaning liquid carriers related applications data
US7943158B2 (en) * 2006-09-07 2011-05-17 BioLargo Life Technologies, Inc Absorbent systems providing antimicrobial activity
US7867510B2 (en) * 2006-09-07 2011-01-11 BioLargo Life Technologies, Inc Material having antimicrobial activity when wet
US8257749B2 (en) * 2007-02-08 2012-09-04 Biolargo Life Technologies, Incorporated Systems providing at least pesticidal activity
WO2009087647A1 (en) * 2008-01-07 2009-07-16 Council Of Scientific & Industrial Research A stabilized iodine-water concentrate formulation useful for protection against iodine deficiency disorders
MX340005B (es) * 2010-04-23 2016-05-18 Univ Nac Autónoma De México Composicion de yodo molecular de uso humano para la prevencion y tratamiento de patologias prostaticas.
WO2012158002A1 (ru) * 2011-05-16 2012-11-22 Begaliev Shokan Sabirkhanovich Лекарственный препарат «renessans», обладающий антибактериальным, противоязвенным и иммуномодулирующим действием
CN102697804B (zh) * 2012-06-07 2014-02-12 维尔信科技（潍坊）有限公司 一种固态分子碘消毒制剂及其制备方法
WO2015080984A1 (en) * 2013-11-27 2015-06-04 BioPharmX, Inc. Solid oral dosage form for breast symptoms
NZ721500A (en) 2014-02-10 2022-11-25 Fred Hutchinson Cancer Center Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
CR20160499A (es) * 2014-03-31 2016-12-05 Iotech Int Inc Composiciones estables de yodo no en complejo y métodos de uso
EA031907B1 (ru) * 2016-03-11 2019-03-29 Тимур Хусаинович Измайлов Шашка иодная дымовая
WO2017185060A1 (en) 2016-04-21 2017-10-26 BioPharmX, Inc. Oral iodine dosage form
CN110072532A (zh) 2016-07-21 2019-07-30 艾欧根有限责任公司 润肤局部消毒剂
CN106727683A (zh) * 2016-12-23 2017-05-31 刘海涛 一种药物制剂在制备治疗幽门螺杆菌感染性疾病的药物中的应用
TW202203900A (zh) * 2020-03-31 2022-02-01 越南商泰明製藥股份有限公司 用於治療癌症、子宮內膜異位症以及癌症或子宮內膜異位症患者的疼痛之二異丙胺化合物以及碘

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2540170C3 (de) * 1975-09-10 1979-01-18 Basf Ag, 6700 Ludwigshafen Verwendung von in organischer Lösung hergestelltem Polyvinylpyrrolidon zur Herstellung von stabilen wäßrigen PoIyvinylpyrrolidon-Jod-Lösungen
US4259322A (en) * 1978-03-20 1981-03-31 Helong Lim Method of treatment of tuberculosis
US4187294A (en) * 1978-07-06 1980-02-05 Nihon Nousan Kougyou Co., Ltd. Method for producing eggs containing a high amount of iodinated amino acids
JPS5663919A (en) * 1979-10-29 1981-05-30 Nippon Nousan Kogyo Kk Remedial composition for diabetes
JPS57140723A (en) * 1981-02-25 1982-08-31 Nippon Nousan Kogyo Kk Preventing composition for hyperlipemia due to neutral fat
US5171582A (en) * 1985-07-31 1992-12-15 Ghent William R Treatment of iodine deficiency diseases
US4816255A (en) * 1985-07-31 1989-03-28 Ghent William R Treatment of iodine deficiency breast syndrome
US5250304A (en) * 1985-07-31 1993-10-05 Ghent William R Treatment of iodine deficiency diseases
US5589198A (en) * 1985-07-31 1996-12-31 943038 Ontario, Inc. Treatment of iodine deficiency diseases
US5629024A (en) * 1994-08-22 1997-05-13 Symbollon Corporation Method of forming an iodine based germicide composition

Also Published As

Publication number Publication date
AU750627B2 (en) 2002-07-25
DE69811105T2 (de) 2003-11-06
PT1024815E (pt) 2003-06-30
IL134778A0 (en) 2001-04-30
AU1122799A (en) 1999-05-17
CN1150904C (zh) 2004-05-26
WO1999021567A1 (en) 1999-05-06
EP1024815B1 (en) 2003-01-29
CA2301503A1 (en) 1999-05-06
JP2003510243A (ja) 2003-03-18
EP1024815A1 (en) 2000-08-09
CA2301503C (en) 2005-01-04
US5885592A (en) 1999-03-23
RU2213564C2 (ru) 2003-10-10
ATE231725T1 (de) 2003-02-15
CN1272789A (zh) 2000-11-08
DK1024815T3 (da) 2003-05-19
DE69811105D1 (de) 2003-03-06
BR9812588A (pt) 2000-07-25
KR100412219B1 (ko) 2003-12-24
KR20010030861A (ko) 2001-04-16
NO20001673L (no) 2000-05-24
JP4187410B2 (ja) 2008-11-26
NO20001673D0 (no) 2000-03-31

Similar Documents

Publication Publication Date Title
ES2191973T3 (es) Composiciones farmaceuticas para la administracion oral de yodo molecular.
ES2170223T3 (es) Composicion farmaceutica que contiene hidratos de carbonato de lantano seleccionados.
DE69604653T2 (de) Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen
IN171746B (es)
ATE429210T1 (de) Orale flüssige zusammensetzungen
IT1245761B (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
IT1275816B1 (it) Composizioni farmaceutiche solide per uso vaginale
CO4230093A1 (es) Derivados del indol y sus usos medicos
CO5060499A1 (es) Metodos y composiciones para el tratamiento de enfermedad de reflujo gastroesofagico
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
PT991409E (pt) Composicoes farmaceuticas de libertacao controlada contendo tiagabina
ATE165239T1 (de) Orale arzeimittelzubereitung enthaltend diclofenac-natrium und eine organische säure
DK0911038T3 (da) Vandfri sammensætning omfattende lactulose
IL70407A (en) Synergistic analgesic pharmaceutical compositions in unit dosage form,comprising an analgesic agent and hydroxyzine
DK1462107T3 (da) Fremgangsmåde til kvindelig kontraception og kit til anvendelse i en sådan fremgangsmåde
IT1265342B1 (it) Composizioni farmaceutiche a base di derivati della glicina
AR005136A1 (es) Compuestos antibioticos oligosacaridos hidrosolubles, una composicion farmaceutica que los contienen y el uso de los mismos para la preparacion de un medicamento
ATE240097T1 (de) Pharmaceutische zusammensetzung enthaltend (+)- ephedrin und einen h1 rezeptor antagonisten
PE33896A1 (es) Composicion farmaceutica para el tratamiento del malestar gastrico
KR910014121A (ko) 위궤양 및 미란 치료용인 시메티딘-피렌제핀 제제
UA39418A (uk) Спосіб лікування виразкової хвороби, асоційованої з helicobacter pylori
RU94013463A (ru) Способ и композиция для лечения заболеваний желудка и двенадцатиперстной кишки и новые производные пге2